Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
08:30am, Friday, 12'th Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a
ALX Oncology to Participate in Upcoming Investor Conferences in September
12:00pm, Friday, 29'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ther
ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript
09:45pm, Tuesday, 12'th Aug 2025
ALX Oncology Holdings Inc. (NASDAQ:ALXO ) Q2 2025 Earnings Conference Call August 12, 2023 4:30 AM ET Company Participants Alan Bart Sandler - Chief Medical Officer Harish Shantharam - Chief Financial
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
08:00am, Tuesday, 05'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
08:00am, Friday, 30'th May 2025
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ther
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
08:00am, Tuesday, 13'th May 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:30am, Thursday, 08'th May 2025
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
08:00am, Friday, 02'nd May 2025
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a p
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and dem
